Unlock instant, AI-driven research and patent intelligence for your innovation.

Indole derivatives

A technology of indole and compounds, applied in the field of novel indole derivatives, can solve problems such as side effects of antidiabetic agents, lactic acidosis, hypoglycemia, etc.

Inactive Publication Date: 2008-01-23
MITSUBISHI TANABE PHARMA CORP
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these antidiabetic agents have various side effects
For example, biguanides cause lactic acidosis; sulfonylureas cause marked hypoglycemia; insulin sensitizers cause edema and heart failure; and alpha-glucosidase inhibitors cause abdominal distension and diarrhea

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Indole derivatives
  • Indole derivatives
  • Indole derivatives

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0162] 4-Chloro-3-(4-ethylphenylmethyl)-1-(β-D-glucopyranosyl)indole

[0163] (1) Under argon atmosphere, reflux overnight 4-chloroindoline (2.88 g) and D-glucose (3.38 g) in ethanol (150 ml)-H 2 O (10 mL). The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 88:12) to obtain 4-chloro-1-(β-D-glucopyranosyl ) indole (3.35 g). APCI-Mass m / Z 316 / 318(M+H). 1 H-NMR (DMSO-d6) δ2.87-3.02 (m, 2H), 3.07-3.12 (m, 1H), 3.20-3.32 (m, 2H), 3.38-3.47 (m, 2H), 3.51-3.60 ( m, 2H), 3.68-3.73(m, 1H), 4.34-4.37(m, 1H), 4.63(d, J=8.3Hz, 1H), 4.93(d, J=5.1Hz, 1H), 5.03(d , J=4.0Hz, 1H), 5.06(d, J=4.5Hz, 1H), 6.53(d, J=8.0Hz, 1H), 6.60(d, J=8.0Hz, 1H), 6.99(t, J = 7.9Hz, 1H).

[0164] (2) Dissolve the above compound (3.3 g) in 1,4-dioxane (150 ml), and add 2,3-dichloro-5,6-dicyano-1,4-benzoquinone in it (2.85 grams). The mixture was stirred at room temperature for 12 hours. Saturated aqueous sodium...

Embodiment 2

[0171] 3-(4-Ethylphenylmethyl)-4-fluoro-1-(β-D-glucopyranosyl)indole

[0172] (1) Under argon atmosphere, reflux 4-fluoroindoline (185 mg) and D-glucose (267 mg) in H 2 O (0.74 mL)-ethanol (9 mL) mixture for 24 hours. The solvent was evaporated under reduced pressure to give crude 4-fluoro-1-(β-D-glucopyranosyl)indoline, which was used in the next step without further purification.

[0173] (2) The above compound was suspended in chloroform (8 mL), and pyridine (0.873 mL), acetic anhydride (1.02 mL) and 4-(dimethylamino)pyridine (catalytic amount) were successively added thereto. After stirring at room temperature for 21 hours, the reaction solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, and the solution was washed twice with 10% aqueous copper(II) sulfate, with saturated aqueous sodium bicarbonate, and dried over magnesium sulfate. Insoluble materials were removed by filtration, and the filtrate was evaporated under reduced pressu...

Embodiment 3

[0180] 4-Chloro-3-(4-ethoxyphenylmethyl)-1-(β-D-glucopyranosyl)indole

[0181] (1) Process the 4-chloro-1-(2,3,4,6-tetra-O-acetyl-β-D- glucopyranosyl)indole and 4-ethoxybenzoyl chloride to give 4-chloro-1-(2,3,4,6-tetra-O-acetyl-β-D- Glucopyranosyl)indol-3-yl 4-ethoxyphenyl ketone. APCI-Mass m / Z630 / 632(M+H). 1 H-NMR (DMSO-d6) δ1.37(t, J=7.0Hz, 3H), 1.69(s, 3H), 1.98(s, 6H), 2.04(s, 3H), 4.11-4.12(m, 2H ), 4.14(q, J=7.3Hz, 2H), 4.28-4.32(m, 1H), 5.29(t, J=9.7HZ, 1H), 5.54(t, J=9.5Hz, 1H), 5.71(t , J=9.2Hz, 1H), 6.32(d, J=9.0Hz, 1H), 7.04(d, J=8.8Hz, 2H), 7.25(d, J=7.5Hz, 1H), 7.35(t, J =8.0Hz, 1H), 7.79(d, 1H), 7.99(d, J=8.8Hz, 2H), 8.07(s, 1H).

[0182] (2) Process the above-mentioned 4-chloro-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)indole in a manner similar to Example 2-(5) -3-yl 4-ethoxyphenyl ketone (500 mg) to give crude 4-chloro-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl ) indol-3-yl 4-ethoxyphenylmethanol was used directly in the next step without further ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

Indole derivatives of formula (I) or a pharmaceutically acceptable salt thereof: wherein R<1> is halogen, or alkyl, R<2> is hydrogen, or halogen, Ar is phenyl, or thienyl, which may be substituted with halogen, alkyl, alkoxy, alkylthio, etc.

Description

technical field [0001] The present invention relates to novel indole derivatives having activity as inhibitors of the sodium-dependent glucose transporter (SGLT) found in the intestine or kidney. Background technique [0002] In the treatment of diabetes, dietary therapy and exercise therapy are very necessary. Insulin or antidiabetic agents are used when these therapies are insufficient to control a patient's symptoms. Currently, biguanides, sulfonylureas, insulin sensitizers, and α-glucosidase inhibitors are used as antidiabetic agents. However, these antidiabetic agents have various side effects. For example, biguanides cause lactic acidosis; sulfonylureas cause marked hypoglycemia; insulin sensitizers cause edema and heart failure; and alpha-glucosidase inhibitors cause abdominal distension and diarrhea. Under the circumstances, the emergence of novel antidiabetic drugs that eliminate these side effects is expected. [0003] Recently, it has been reported that hyperg...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D405/04C07D409/14C07D405/14C07D401/14A61K31/404A61P3/10
CPCC07D401/14C07D405/14C07D405/04C07H19/22C07D409/14A61P3/04A61P3/06A61P3/10A61P9/10A61P9/12A61P17/02A61P43/00A61K31/7048A61K31/7056A61K31/706C07H7/06
Inventor 野村纯宏山元康王
Owner MITSUBISHI TANABE PHARMA CORP